← Search & browse all drugs

atosiban

G02CX01

Forms & Strengths

Solution for injection: 6.74 mg/mL (6.75 mg of atosiban acetate, equivalent to 6.74 mg of atosiban) in 0.9 mL or 5 mL or 10 mL ampoules
Solution for injection: 6.75 mg of atosiban acetate in 0.9 mL, 5 mL or 10 mL ampoules, equivalent to 6.74 mg of atosiban
Concentrate for solution for infusion: 6.75 mg of atosiban acetate in 0.9 mL or 5 mL vials

Adult Dosing

Initial dose: 6.75 mg bolus injection
Maintenance dose: 18 mg/hour by continuous infusion for 2 hours
Maximum dose: 18 mg/hour for up to 45 hours if clinically needed

Pediatric Dosing

Not established for pediatric patients
Not recommended for use in pediatric patients due to limited data

Indications

Delaying imminent preterm birth in pregnant women with intact membranes
Between 24 and 33 weeks of gestation with a high risk of preterm birth within 48 hours

Mechanism of Action

Competitively inhibits oxytocin and vasopressin at the receptor level
Blocks oxytocin-induced contraction of uterine smooth muscle

Contraindications

Hypersensitivity to atosiban or any excipients
Placental abruption
Eclampsia or severe preeclampsia
Severe fetal distress

Adverse Reactions

Nausea and vomiting
Headache
Dizziness
Nasal congestion
Urticaria

Drug Interactions

No clinical significant interactions with heparin, hydrocortisone, salbutamol, or nifedipine
Caution with tocolytic or uterotonic agents due to increased risk of adverse reactions

Curated Content: Needs Vetting Before Put to Clinical Use